Dipeptidyl peptidase-4 inhibitors, a class of drug that reduces blood sugar in type 2 diabetes, were associated with less amyloid accumulation in the brain and slower cognitive decline in patients.
Dipeptidyl peptidase-4 inhibitors, a class of drug that reduces blood sugar in type 2 diabetes, were associated with less amyloid accumulation in the brain and slower cognitive decline in patients.